Research Topics
| Paul J MoscaSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
When a chance to cut is not a chance to cure: a future for palliative surgery?Paul J Mosca
Ann Surg Oncol 18:3235-9. 2011....- Melanoma arising in a skin graftJennifer G Hall
Department of General Surgery, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27710, USA
Ann Plast Surg 54:92-6. 2005..This exceptional presentation of cutaneous melanoma is discussed to highlight key principles of skin grafting in relation to the management of malignant melanoma... - Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNAMichael A Morse
Department of Medicine, Medical Center, Box 3233, Durham, North Carolina 27710, USA
Cancer Invest 21:341-9. 2003..We conclude that it is feasible and safe to administer mRNA-loaded DC to patients with advanced malignancies... - Proteomics for monitoring immune responses to cancer vaccinesPaul J Mosca
Department of Surgery, Duke University Medical Center, Box 2606 DUMC, Durtham, NC 27710, USA
Curr Opin Mol Ther 5:39-43. 2003..Advances in miniaturization and automation may also permit characterization of the immune response more rapidly and from smaller amounts of biological material than is possible with existing assay systems... - Dendritic cell maturation in active immunotherapy strategiesMichael A Morse
Department of Mecine and Surgery, Duke University Medical Center, Durham, NC 27710, USA
Expert Opin Biol Ther 2:35-43. 2002.... 
Can surgeons improve survival in stage IV melanoma?Paul J Mosca
Department of Surgery, Lehigh Valley Hospital, Allentown, PA, USA
J Surg Oncol 97:462-8. 2008..Incorporating these results into new approaches using multimodality treatment may enhance survival in patients with stage IV melanoma...- Current status of dendritic cell immunotherapy of malignanciesPaul J Mosca
Departments of Surgery and Medicine, Duke University Medical Center, Durham, North Carolina, USA
Int Rev Immunol 22:255-81. 2003..Clinical responses such as stability of disease and tumor regressions have been reported in some patients, particularly with melanoma, myeloma, and prostate cancer... - Immune monitoringPaul J Mosca
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Cancer Treat Res 123:369-88. 2005..It should be the goal and expectation that this rational approach to immune monitoring will allow the critical appraisal of the most promising vaccine candidates in the context of pivotal, multi-center trials... - Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplantsMichael A Morse
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Hematother Stem Cell Res 11:659-68. 2002.... - Surgical management of cutaneous melanoma: current practice and impact on prognosisPaul J Mosca
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
Adv Surg 38:85-119. 2004 - Immunotherapy of surgical malignanciesMichael A Morse
Duke University Medical Center, Durham, North Carolina, USA
Curr Probl Surg 41:15-132. 2004 - Histopathologic characteristics, recurrence patterns, and survival of 129 patients with desmoplastic melanomaKatherine E Posther
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Ann Surg Oncol 13:728-39. 2006..Desmoplastic melanoma (DM) has been associated with higher local recurrence rates than other types of cutaneous melanoma. Current controversies regarding locoregional treatment strategies warrant further investigation... - Dendritic cell vaccinesPaul J Mosca
Duke Comprehensive Cancer Center Duke University Medical Center, Durham, NC 27710, USA
Front Biosci 12:4050-60. 2007..The emphasis of dendritic cell immunotherapy research is increasingly shifting toward the development of strategies to increase the potency of dendritic cell vaccine preparations... - Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligandPaul J Mosca
Department of General and Thoracic Surgery, Pathology, Immunology, Duke University Medical Center, Durham, North Carolina 27710, USA
J Leukoc Biol 72:546-53. 2002..The ability to generate phenotypically mature, IL-12-producing DC1 from peripheral blood mononuclear cells mobilized by Flt3L will have important implications for the development of effective cancer immunotherapy strategies... - A multi-institutional experience of isolated limb infusion: defining response and toxicity in the USGeorgia M Beasley
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Am Coll Surg 208:706-15; discussion 715-7. 2009..Establishing response and toxicity to ILI as compared with hyperthermic isolated limb perfusion is important for optimizing future regional chemotherapeutic strategies in melanoma... - Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILIJames C Padussis
Department of Surgery, Duke University Medical Center, Durham, NC, USA
Int J Hyperthermia 24:239-49. 2008..This paper reviews progress in these two key areas of active investigation... - Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor responseThomas A Aloia
Division of Surgical Oncology, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
Arch Surg 140:1115-20. 2005....